No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
DongBang Medical Co., Ltd., established in 1985 and headquartered in Seongnam-si, South Korea, is a prominent manufacturer and distributor specializing in a wide array of medical devices, bio medical solutions, cosmetic devices, and aesthetic fillers. The company's product portfolio includes hyaluronic acid (HA) fillers, marketed under brand names such as ELASTY GRAND, ELASTY DEEP PLUS, and ELASTY G PLUS, which are utilized for facial wrinkle improvement and volume restoration. They also offer various aesthetic threads, including ELASTY LINE, ELASTY MESHFILL, and ELASTY-V BARB, alongside essential medical consumables like cannulas, needles, and syringes. Beyond medical aesthetics, DongBang Medical provides an extensive range of skincare and haircare products. This includes moisturizing masks (Hyaluronic acid, Beta-Glucan), the FILL US patch, and specialized lines such as AG Solution (calming, defying, regenerating), AT Solution (cleansing, moisturizing, concentrated), AC Solution (clarifying, refining), and Hair Solution (shampoo, treatment, tonic), complemented by HA ESSENCE. Furthermore, their offerings extend to traditional healthcare items like hand acupuncture devices (e.g., hand acupuncture, spring hand acupuncture tube) and various other general goods such as pillows, charcoal, heat-resistant silicone, and cupping tools. DongBang Medical has a significant international presence, exporting its products to approximately 50 countries across North America, South America, Europe, Asia, and the Middle East.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
DongBang Medical Co., Ltd., established in 1985 and headquartered in Seongnam-si, South Korea, is a prominent manufacturer and distributor specializing in a wide array of medical devices, bio medical solutions, cosmetic devices, and aesthetic fillers. The company's product portfolio includes hyaluronic acid (HA) fillers, marketed under brand names such as ELASTY GRAND, ELASTY DEEP PLUS, and ELASTY G PLUS, which are utilized for facial wrinkle improvement and volume restoration. They also offer various aesthetic threads, including ELASTY LINE, ELASTY MESHFILL, and ELASTY-V BARB, alongside essential medical consumables like cannulas, needles, and syringes. Beyond medical aesthetics, DongBang Medical provides an extensive range of skincare and haircare products. This includes moisturizing masks (Hyaluronic acid, Beta-Glucan), the FILL US patch, and specialized lines such as AG Solution (calming, defying, regenerating), AT Solution (cleansing, moisturizing, concentrated), AC Solution (clarifying, refining), and Hair Solution (shampoo, treatment, tonic), complemented by HA ESSENCE. Furthermore, their offerings extend to traditional healthcare items like hand acupuncture devices (e.g., hand acupuncture, spring hand acupuncture tube) and various other general goods such as pillows, charcoal, heat-resistant silicone, and cupping tools. DongBang Medical has a significant international presence, exporting its products to approximately 50 countries across North America, South America, Europe, Asia, and the Middle East.
